EntryPoint Capital’s Anika Therapeutics ANIK Stock Holding History

EntryPoint Capital’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,028	Closed	-$256K	–	608
2025 Q1	$256K	Buy	+17,028	New	+$283K	0.12%	420
2024 Q1	–	Sell	-1,937	Closed	-$43.9K	–	1410
2023 Q4	$43.9K	Buy	+1,937	New	+$40.1K	0.04%	792

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AFA

Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

EntryPoint Capital's ANIK Position: Q2 2025 in Review

EntryPoint Capital sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 17,028 shares — an estimated $256K sold.

EntryPoint Capital first reported a position in ANIK in Q4 2023 and held it in 2 quarters. The position peaked at $256K in Q1 2025. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

EntryPoint Capital reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
EntryPoint Capital sold 17,028 Anika Therapeutics shares in Q2 2025, an estimated $256K.
EntryPoint Capital first reported a position in Anika Therapeutics in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's Anika Therapeutics position peaked at $256K in Q1 2025.
103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.